Recombinant Mouse Rab5a Protein, Myc/DDK-tagged

• Cat.No.: Rab5a-5326M
• Product Overview: Purified recombinant protein of mouse full-length RAB5A, member RAS oncogene family (Rab5a), with C-terminal MYC/DDK tag, expressed in HEK293T cells.

Specification

• Description: Small GTPase which cycles between active GTP-bound and inactive GDP-bound states. In its active state, binds to a variety of effector proteins to regulate cellular responses such as of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes. Active GTP-bound form is able to recruit to membranes different sets of downstream effectors directly responsible for vesicle formation, movement, tethering and fusion. RAB5A is required for the fusion of plasma membranes and early endosomes. Contributes to the regulation of filopodia extension. Required for the exosomal release of SDCBP, CD63, PDCD6IP and syndecan. Regulates maturation of apoptotic cell-containing phagosomes, probably downstream of DYN2 and PIK3C3.
• Source: HEK293T
• Species: Mouse
• Tag: Myc/DDK
• Molecular Mass: 23.6 kDa
• Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining
• Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles.
• Storage: Store at -80 centigrade after receiving vials.
• Concentration: >50 μg/mL as determined by microplate BCA method
• Storage Buffer: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol.

Gene Information

• Gene Name: Rab5a RAB5A, member RAS oncogene family [ Mus musculus (house mouse) ]
• Official Symbol: Rab5a
• Synonyms: RAB5A; RAB5A, member RAS oncogene family; ras-related protein Rab-5A; AI663973; AU021172; 2410015H04Rik
• Gene ID: 271457
• mRNA Refseq: NM_025887
• Protein Refseq: NP_080163
• UniProt ID: Q9CQD1

Reviews

09/12/2021

If researchers require specific variants or modifications of RAB5A protein, the manufacturer can work with them to provide customized products tailored to their needs.

04/11/2020

Their expertise can help troubleshoot problems, suggest alternative approaches, or provide recommendations for optimizing experimental protocols.

06/17/2018

This level of support saves researchers time and resources, enabling them to focus on the scientific aspects of their work and accelerate the overall progress of their studies.

Q&As

Can targeting RAB5A be a therapeutic approach in cancer treatment?

Research suggests that modulating RAB5A activity may be a viable therapeutic strategy in cancer treatment.

How is RAB5A implicated in clinical applications?

RAB5A is associated with various cellular processes, and its dysregulation has been linked to several diseases.

How does RAB5A contribute to neurodegenerative diseases?

RAB5A dysfunction has been implicated in neurodegenerative diseases, affecting vesicle trafficking and cellular homeostasis in neurons.

Are there diagnostic implications of RAB5A in cancer?

Yes, altered levels of RAB5A expression can serve as potential diagnostic markers for certain cancers.

Are there ongoing clinical trials targeting RAB5A in neurodegenerative diseases?

Some clinical trials are exploring interventions targeting RAB5A to assess their potential in managing neurodegenerative conditions.